RecruitingNCT07210112
Psilocybin with or without trazodone for treatment-resistant depression
About this title
Read the official source — NCT07210112Medication studyAges 18+France
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- ParisSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 30, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 112
- Sponsor
- Centre Hospitalier St Anne
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France
- Age range
- Over 18 Years
- Official registry ID
- NCT07210112
- Official title
Show the full official title
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Recruitment & locations
RecruitingParis
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Centre Hospitalier St Anne.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg, Placebo of psilocybin and Placebo of trazodone.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
